An operation that targets the nerves connected to the kidney has been found to significantly reduce blood pressure in patients with hypertension, according to the results of a clinical trial led in the UK by Queen Mary University of London and Barts Health NHS Trust, and supported by the National Institute for Health Research (NIHR).
If the findings are confirmed in more extensive clinical trials, the surgery could offer hope to patients with high blood pressure who do not respond to drugs, and are at increased risk of cardiovascular diseases, including stroke and heart attack.
The international clinical trial, carried out from 2017 to 2018 at St Bartholomew’s Hospital in the UK by the NIHRBarts Biomedical Research Centre, tested a one-hour operation called ‘renal denervation’, which uses ultrasound energy to disrupt the nerves between the kidneys and the brain that carry signals for controlling blood pressure.
Significant reduction in blood pressure
146 patients in the United States, France, Germany, the Netherlands, Belgium and the United Kingdom were randomised to receive either renal denervation or a ‘sham procedure’ – the surgical equivalent of a placebo. Patients also remained off blood pressure medications for two months unless specified blood pressure levels were exceeded.
After two months, the renal denervation group experienced an 8.5 mm Hg reduction in blood pressure, which was a 6.3 mm Hg greater reduction compared with the sham group.
More than 66 per cent of subjects treated with renal denervation demonstrated a 5 mm Hg or greater reduction in blood pressure, compared with 33 per cent in the sham group.
No major adverse events were reported in either group, and the blood pressure lowering effect of renal denervation was consistent across sex and ethnicity.
An alternative to lifelong medications
UK Principal Investigator Dr Melvin Lobo from Queen Mary’s William Harvey Research Institute and Barts Health NHS Trust said: “These results leave us clinicians in no doubt that this ultrasound-based therapy works to improve blood pressure control – at least in the short term. Further larger trials will be needed to confirm the efficacy and safety of the technology, but we hope that they could lead to renal denervation therapy being offered as an alternative to lifelong medications for hypertension.”
The study has limitations including the short follow-up time of two months. This was done for safety reasons to minimise the duration of patients being off antihypertensive medications. Longer follow-up of this trial and additional numbers of treated patients will be necessary to provide greater assurance of safety and to exclude rare adverse events.
The Latest on: Hypertension
via Google News
The Latest on: Hypertension
- One-size-fits-all approach does not work for treating pregnant women with hypertensionon May 11, 2020 at 3:23 pm
Treatment guidelines for hypertension in pregnancy suggest that more women should be on medication to control their blood pressure.
- One-size-fits-all approach doesn't work for treating hypertension in pregnancyon May 11, 2020 at 1:11 pm
Treatment guidelines for hypertension in pregnancy suggest that more women should be on medication to control their blood pressure. However, new research led by the Centre for Health Evaluation and ...
- Global Pulmonary Hypertension Industry Analysis 2016-2024: Pipeline, Epidemiology, Competitive Analysis, Drug Sales and Shares - ResearchAndMarkets.comon May 11, 2020 at 4:43 am
The "Global Pulmonary Hypertension Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering. This research report provides comprehensive insights into the ...
- New guidelines will help countries across the world to manage hypertensionon May 10, 2020 at 10:21 pm
A new global set of guidelines released today (International Society of Hypertension 2020 Global Hypertension Practice Guidelines) will help countries across the world manage hypertension, which is ...
- High blood pressure - the one breakfast swap to lower your risk of deadly hypertensionon May 6, 2020 at 9:00 pm
HIGH blood pressure risk could be lowered by making some diet or lifestyle changes. You could lower your chances of developing deadly hypertension symptoms and signs by making this easy breakfast swap ...
- International Society of Hypertension release global practice guidelineson May 6, 2020 at 2:03 am
High blood pressure (hypertension) is the leading cause of death in the world affecting more than 1.4 billion people and accounting for more than 28,000 deaths each day. Today, the International ...
- No link between hypertension drugs and COVID-19 risk, study ruleson May 5, 2020 at 7:02 am
A new study has concluded that there is no link between blood pressure drugs and the risk of COVID-19, reassuring concerned medical professionals.
- Urate-lowering therapy exerts protective effects against hypertension development in patients with gouton May 4, 2020 at 9:26 am
Many studies have demonstrated that hyperuricemia is associated with hypertension (HTN) development, but few studies have explored whether urate-lowering therapy (ULT), which reverses hyperuricemia, ...
- Acceleron Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Sotatercept in Pulmonary Arterial Hypertensionon May 4, 2020 at 4:54 am
Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfami ...
via Bing News